KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

West Pharmaceutical Services (WST) Cash from Restructuring (2018 - 2026)

West Pharmaceutical Services has reported Cash from Restructuring over the past 4 years, most recently at $900000.0 for Q1 2026.

Quarterly Cash from Restructuring rose 12.5% to $900000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, up 112.5% year-over-year, with the annual reading at $5.4 million for FY2025, N/A changed from the prior year.
Cash from Restructuring was $900000.0 for Q1 2026 at West Pharmaceutical Services, up from $800000.0 in the prior quarter.
Over five years, Cash from Restructuring peaked at $900000.0 in Q1 2026 and troughed at $800000.0 in Q1 2025.